Back to blog

    Remote Specimen Collection in Clinical Trials: A Practical Guide

    Home specimen collection kit ready for use

    Remote specimen collection means a trial specimen is taken away from the study site, at the participant’s home or at a nearby provider, and then sent to a designated laboratory for processing. It works when three things are settled before the first participant enrolls: which specimen types suit the assay, who collects each one, and how the sample travels and is documented until it reaches the lab. We built our clinical trial laboratory work around those handoffs: mobile phlebotomy, courier specimen pickup and regulatory-aligned data delivery.

    This guide is for sponsors, CROs, study directors and site teams who are deciding how to bring specimen collection closer to participants without losing data quality.

    Kohealth Labs
    kohealthlabs.com
    Simplify Remote Trial Specimen Logistics
    KoHealth Labs supports clinical trials with mobile phlebotomy, specimen pickup and transportation, laboratory testing, and electronic results reporting.
    Visit

    TL;DR

    • Under FDA’s September 2024 guidance, a protocol can use home kits, remote trial personnel or local health care providers for collection, as long as it specifies the instructions and the specimens go to designated laboratories.
    • Match the method to the analyte: self-collection suits some specimen types, while others need a trained collector.
    • Home conditions are less controlled than a site, so stability, labeling, shipping and chain of custody must be designed in, not added later.
    • Document collection time, method, conditions, shipment dates and receipt temperature for every specimen.
    • A single laboratory partner that handles phlebotomy, pickup, testing and data delivery removes the handoffs where remote samples most often go wrong.

    What remote specimen collection means in a trial

    A traditional trial asks every participant to come to the site for each blood draw or swab. Remote collection moves that step. FDA’s guidance on decentralized elements, issued in September 2024, describes specimens collected with home kits, by remote trial personnel or by local health care providers, then sent to designated laboratories. The protocol should state the instructions.

    An academic review of remote patient-centric sampling (Maass and colleagues, 2022) frames it the same way: collection away from the site by the participant, a caregiver or an at-home nurse. The same review notes that it can allow less invasive, less painful or lower-volume sampling.

    In practice there are three models:

    • Self-collection. The participant uses a kit and returns it by mail or courier.
    • Professionally assisted collection at home. A mobile phlebotomist or nurse visits the participant.
    • Local provider collection. The participant goes to a nearby clinic or draw location instead of the study site.

    Most real studies mix them. A participant may self-collect a swab at home and have a phlebotomist draw venous blood at selected visits.

    Which specimen types work remotely

    Suitability depends on the analyte and the assay, not on convenience. The 2022 review identifies dried blood spots, microsampling devices, saliva and other alternative matrices as options that can support collection at home. A 2026 narrative review by Horvath and colleagues reports that self-collected vaginal, anorectal and oropharyngeal swabs, and urine, can be feasible for certain sexually transmitted infection research, with swab type, transport medium and stability depending on the assay.

    A working way to sort specimen types:

    Specimen Typical remote route What to confirm before choosing it
    Dried blood spot Self-collection with mailed kit Assay validated on this matrix; participant technique
    Urine Self-collection Preservative, volume, time to lab
    Swabs (oropharyngeal, vaginal, anorectal) Self-collection with instructions Swab and transport medium match the assay
    Saliva Self-collection Stability at ambient temperature
    Venous blood (serum, plasma, whole blood) Mobile phlebotomy or local provider Processing time, centrifugation, temperature
    Specimens needing frozen or refrigerated transport Professionally assisted collection plus courier Cold chain from collection to receipt

    When the endpoint depends on a venous draw, a trained phlebotomist keeps the specimen equivalent to what a site would produce. Our guide to mobile phlebotomy in clinical trials covers that model for sponsors and CROs, and the three mobile phlebotomy models with FDA-ready SOPs help coordinators choose between them.

    Specimen type also affects whether people can do it. In a 2023 feasibility study of 133 remote visits, 87.5% of baseline dried-blood-spot samples and 83.3% of baseline nail samples were returned, and every returned sample was processed. But 77.7% of hair samples were insufficient or lacked a marked scalp end, and the researchers judged hair collection infeasible in that framework. Return rates and adequacy vary by specimen type, so pilot each one.

    Baseline return and adequacy results by specimen type

    Designing the process step by step

    The steps below follow how a remote collection workflow is usually built. At each one we note where it goes wrong and what we handle for trials.

    1. Define the collection and handling procedures in the protocol

    FDA’s E18 guidance on genomic sampling says collection, processing, transport and storage procedures should be defined, documented, tailored to the specimen and assay, and verified before implementation. Genomic sampling is the guidance’s subject, but the discipline applies to any remote specimen.

    Where it goes wrong: procedures written for a site (a centrifuge in the room, a freezer down the hall) quietly fail when the specimen is collected on a kitchen table. Write the home version separately and state each requirement in terms a participant or a visiting phlebotomist can follow.

    2. Build the kit and the instructions together

    The 2023 feasibility study mailed participants biospecimen kits with written instructions, a video link and prepaid return envelopes, and staff guided participants by telephone during the visits. The Maass review recommends detailed instructions, training, a log of collection times or other data capture, and pilot testing, because home settings give less control over temperature, processing time and adherence.

    Where it goes wrong: kits that rely on a long document nobody reads. Keep steps short, use pictures or video, and make the participant record the collection time.

    3. Decide who collects what

    Self-collection costs the least per visit but leaves technique to the participant. Assisted collection costs more but protects the sample. Choose by endpoint. Primary endpoint specimens and anything with a narrow processing window usually justify a trained collector. Where a participant has limited mobility or the protocol includes older or home-bound populations, a visiting phlebotomist is also the more reliable route.

    We provide mobile phlebotomy for clinical research, and the same laboratory then receives and tests the specimen, so the collector and the lab work from one set of instructions.

    4. Plan shipping and cold chain

    Shipping is where remote studies lose the most samples. Stability limits decide whether a specimen can travel by mail or needs a courier, and temperature needs decide the packaging. Our specimen cold chain guide walks through temperature control across the journey, and our clinical trial specimen pickup guide covers how pickups are arranged between sites, participants and the lab.

    The Maass review also flags that remote shipping raises privacy, labeling and chain-of-custody issues, and discusses alternative return addresses, labeling devices or containers, and training as operational options. A kit mailed to a home should not announce a participant’s condition on the outside of the box.

    5. Document every handoff

    E18 recommends recording collection timing, method, location and conditions, and documenting changes or deviations over the life of the sample. It also recommends recording chain of custody and the timing of each step across collection, handling, analysis and aliquots, plus quality-control programs. Shipment and receipt dates and the approximate specimen temperature at receipt should be documented, and deviations from the intended shipping parameters recorded.

    Where it goes wrong: documentation split across a participant’s paper log, a courier tracking page and the lab’s receiving system, with no single record. Decide up front which system is the record, and how deviations are flagged back to the study team.

    5. Document every handoff

    6. Pilot before you scale

    Run a small pilot with the real kit, the real courier route and the real assay. Measure return rate, adequate volume, time from collection to receipt and temperature at receipt. The feasibility study’s hair-sample result is a reminder that a method can look sensible on paper and still fail in participants’ hands.

    Benefits and what to plan around

    The benefits are concrete. Remote collection can reduce participant travel and burden, and it supports wider participation. FDA’s roundup on the final guidance notes that decentralized elements allow trial activities to occur at locations convenient for participants, including in-home visits with remote trial personnel or visits with local health care providers.

    The design points to plan for are the ones the research names: home conditions, participant technique, shipping and stability, privacy and chain of custody. Maass and colleagues argue that remote sampling should be planned around stability and validation, not just participant convenience. That is the reason to choose collection method, packaging and courier timing as one design decision.

    What the U.S. framework asks of sponsors

    The main U.S. reference is FDA’s final guidance, Conducting Clinical Trials With Decentralized Elements, issued in September 2024. It gives recommendations to sponsors, investigators and other parties on using remote activities such as telehealth visits, in-home visits and local provider visits. It sets out that specimens collected through home kits, remote trial personnel or local providers go to designated laboratories, and that the protocol should specify the instructions.

    For your own study, confirm current requirements with your regulatory team, your IRB and the FDA pages for your product type. Guidance is updated over time, so check FDA’s site for the version in force when you finalize the protocol.

    Questions to ask a laboratory partner

    Whether you run one study or several, the laboratory is the part of the remote model that has to hold everything together. Useful questions for any central or specialty laboratory:

    • Can the lab supply or support collection, not only receive samples?
    • Does it arrange courier pickup with temperature control?
    • Can results and specimen records move into your systems in a format your data management team expects?
    • Will one team own communication with your coordinators?

    We offer collection, specimen pickup, testing and electronic results reporting as a connected service, with EMR and LIS integration and onboarding and training for the study team. For molecular endpoints, our PCR testing guide for CROs explains how the laboratory side supports study protocols.

    Promo: one laboratory partner for the whole remote workflow

    Our clinical trials service covers laboratory testing, specimen collection and management, biomarker analysis and flexible diagnostic solutions built around study-specific requirements. That includes mobile phlebotomy, courier specimen pickup and regulatory-aligned data delivery, so remote collection does not depend on separate vendors for each leg. See how it fits your protocol on our clinical trials page.

    Kohealth Labs

    If you want to talk through your kit, courier route or visit schedule, book a conversation with our team.

    Our perspective

    Remote collection succeeds or fails in the handoffs: from participant to collector, collector to courier, courier to laboratory, laboratory to your data system. Every handoff is a place where time, temperature or a label can slip.

    That is why we think of a trial laboratory as a partner, not a receiving dock. We support study protocols, simplify specimen logistics and deliver reliable laboratory data, and we do it through direct communication with the people running your study. Mobile phlebotomy, specimen pickup, testing and electronic reporting are connected services at KoHealth Labs, so one team can see the whole path of a specimen.

    The research is clear that remote sampling should be designed around stability and validation. We encourage study teams to bring the laboratory in at protocol design, before kits are printed and routes are set, so collection method, packaging and timing are chosen together.

    Kohealth Labs

    FAQ

    Can all specimen types be collected remotely in a trial?

    No. Suitability depends on the analyte and the assay. Dried blood spots, saliva, urine and some self-collected swabs can support home collection, according to published reviews, while specimens with tight processing windows are better collected by a trained phlebotomist. Pilot each specimen type before launch.

    Who is allowed to collect specimens outside the trial site?

    FDA’s September 2024 guidance describes home kits, remote trial personnel and local health care providers as routes, with the protocol specifying instructions. Your protocol should name who does what for each visit and specimen.

    What should be documented for a remotely collected specimen?

    FDA’s E18 guidance recommends recording collection timing, method, location and conditions, chain of custody across each step, shipment and receipt dates, and temperature at receipt, along with any deviations.

    How do you reduce unusable samples from home collection?

    Give participants short, visual instructions, record the collection time, and use prepaid return packaging. A 2023 feasibility study combined written instructions, a video link and telephone guidance. Pilot first, since return rates and adequacy differed by specimen type.

    Sources

    For more information about our diagnostic testing, clinical research laboratory services, or partnership opportunities, visit https://kohealthlabs.com or contact KoHealth Labs at (469) 792-8439 and ask for Amy Patterson.